IDEAYA Launches Trial for Precision Cancer Drug, Bets on In-House Pipeline

SOUTH SAN FRANCISCO, CA – March 09, 2026 – IDEAYA Biosciences has initiated a critical new phase in the fight against some of the most challenging cancers, announcing today that the first patient has been dosed in a Phase 1 clinical trial for its investigational drug, IDE892. The study marks a significant step forward for precision oncology, as IDE892 is designed to selectively target solid tumors with a specific genetic vulnerability known as MTAP deletion, a feature common in aggressive cancers like pancreatic and non-small cell lung cancer (NSCLC).

This milestone is part of a broader strategic update from the company, which includes a decisive pivot to prioritize its wholly-owned therapeutic pipeline and the advancement of another promising program targeting a different genetic weakness in cancer cells. The move signals strong confidence in its internal research and development engine and its unique approach to treating genetically defined cancers.

A New Precision Attack on Cancer's Achilles' Heel

At the heart of IDEAYA's strategy is a powerful concept in modern oncology known as "synthetic lethality." This approach exploits a cancer cell's existing genetic flaws to create a fatal weakness. Healthy cells have multiple redundant systems to survive, but cancer cells that have lost one of these systems through mutation become critically dependent on a backup pathway. A drug that blocks this backup pathway can selectively kill cancer cells while leaving healthy cells unharmed.

The most successful example of this to date is the use of PARP inhibitors in patients with BRCA mutations. IDEAYA is applying a similar principle to tumors with MTAP deletion. The loss of the MTAP gene, which occurs in approximately 15% of all solid tumors and up to 40% of pancreatic cancers, forces cancer cells into a state of dependency on two other enzymes: PRMT5 and MAT2A. IDE892 is a highly specialized PRMT5 inhibitor designed to be exceptionally effective in this exact scenario.

"We designed IDE892 with potential best-in-class properties, including specific biophysical and pharmacokinetic properties that we believe will maximize its therapeutic window and clinical efficacy," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, in a statement. The company reports that in preclinical studies, IDE892 demonstrated an approximately 1,400-fold greater selectivity for the PRMT5 enzyme complex found in MTAP-deleted cells compared to the complex in normal cells. This high degree of precision is crucial for maximizing anti-tumor activity while minimizing potential side effects.

The Phase 1 trial will first evaluate IDE892 as a monotherapy. Looking ahead to mid-2026, the company plans to test it in combination with IDE397, its MAT2A inhibitor. This dual-pronged attack is the cornerstone of its synthetic lethality strategy for this patient population. Preclinical data for this combination has been compelling, showing "durable complete responses" in animal models at well-tolerated doses, providing a strong rationale for its advancement into human trials.

Strategic Shift: A Bold Bet on a Proprietary Pipeline

In a move that underscores its confidence in its internal programs, IDEAYA also announced a significant strategic shift. The company will deprioritize its clinical combination activities involving Trodelvy, an antibody-drug conjugate from Gilead Sciences, and will conclude enrollment in the ongoing trials. Instead, it will channel its resources into accelerating its wholly-owned MTAP-deleted and CDKN2A programs.

This decision is not seen as a setback but rather as a calculated maneuver to focus on assets with the highest potential for long-term value and patient impact. By concentrating on its proprietary pipeline, IDEAYA retains full control over development and future commercialization, a strategy that has been met with positive reactions from industry analysts. This focus allows the company to build a deeply interconnected portfolio of therapies that can be rationally combined to address specific cancer genotypes.

The move highlights a growing trend in the biotech industry where smaller, innovation-driven companies are leveraging deep scientific expertise to build valuable, wholly-owned franchises rather than relying solely on larger pharmaceutical partners. For IDEAYA, the bet is clear: the future of its success lies in the unique synthetic lethality platforms it has built from the ground up.

Charting the Future with Next-Generation Targets

While the IDE892 trial is a major focus, IDEAYA is simultaneously building the next wave of its precision oncology pipeline. The company is advancing a first-in-class program targeting tumors with a CDKN2A deficiency. The CDKN2A gene is a critical tumor suppressor, and its loss is a frequent event in many cancers—notably, it is reported to be deficient in over 80% of pancreatic cancer cases.

Significantly, the MTAP and CDKN2A genes are located close to each other on chromosome 9p21, meaning they are often deleted together. This biological link creates a powerful strategic synergy for IDEAYA, opening the door for future combination therapies between its MTAP-targeted drugs and its forthcoming CDKN2A inhibitor. The company is on track to nominate a development candidate for this program in the second half of 2026, with plans to file for an Investigational New Drug (IND) application in the first half of 2027.

For the thousands of patients diagnosed each year with MTAP-deleted or CDKN2A-deficient cancers, for which no targeted therapies currently exist, these programs represent a new frontier of hope. By meticulously mapping the genetic vulnerabilities of cancer and designing highly selective drugs to exploit them, IDEAYA Biosciences is positioning itself at the forefront of the precision medicine revolution, aiming to turn once-intractable diseases into manageable conditions.